IDNA vs. IBB
Compare and contrast key facts about iShares Genomics Immunology and Healthcare ETF Genomics Immunology and Healthcare Fund (IDNA) and iShares Nasdaq Biotechnology ETF (IBB).
IDNA and IBB are both exchange-traded funds (ETFs), meaning they are traded on stock exchanges and can be bought and sold throughout the day. IDNA is a passively managed fund by iShares that tracks the performance of the NYSE FactSet Global Genomics and Immuno Biopharma Index. It was launched on Jun 11, 2019. IBB is a passively managed fund by iShares that tracks the performance of the NASDAQ Biotechnology Index. It was launched on Feb 5, 2001. Both IDNA and IBB are passive ETFs, meaning that they are not actively managed but aim to replicate the performance of the underlying index as closely as possible.
Scroll down to visually compare performance, riskiness, drawdowns, and other indicators and decide which better suits your portfolio: IDNA or IBB.
Performance
IDNA vs. IBB - Performance Comparison
Returns By Period
In the year-to-date period, IDNA achieves a 0.94% return, which is significantly higher than IBB's -0.51% return.
IDNA
0.94%
-4.54%
-5.92%
17.65%
-2.89%
N/A
IBB
-0.51%
-6.35%
-2.08%
14.67%
3.45%
3.44%
Key characteristics
| IDNA | IBB | |
|---|---|---|
| Sharpe Ratio | 0.65 | 0.77 |
| Sortino Ratio | 1.04 | 1.16 |
| Omega Ratio | 1.12 | 1.14 |
| Calmar Ratio | 0.22 | 0.42 |
| Martin Ratio | 2.66 | 3.49 |
| Ulcer Index | 5.28% | 3.94% |
| Daily Std Dev | 21.65% | 17.91% |
| Max Drawdown | -68.26% | -62.85% |
| Current Drawdown | -57.25% | -22.76% |
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
IDNA vs. IBB - Expense Ratio Comparison
Both IDNA and IBB have an expense ratio of 0.47%.
Correlation
The correlation between IDNA and IBB is 0.90, which is considered to be high. That indicates a strong positive relationship between their price movements. Having highly-correlated positions in a portfolio may signal a lack of diversification, potentially leading to increased risk during market downturns.
Risk-Adjusted Performance
IDNA vs. IBB - Risk-Adjusted Performance Comparison
This table presents a comparison of risk-adjusted performance metrics for iShares Genomics Immunology and Healthcare ETF Genomics Immunology and Healthcare Fund (IDNA) and iShares Nasdaq Biotechnology ETF (IBB). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
Dividends
IDNA vs. IBB - Dividend Comparison
IDNA's dividend yield for the trailing twelve months is around 1.21%, more than IBB's 0.33% yield.
| TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
IDNA iShares Genomics Immunology and Healthcare ETF Genomics Immunology and Healthcare Fund | 1.21% | 1.04% | 0.54% | 0.70% | 0.26% | 0.80% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
IBB iShares Nasdaq Biotechnology ETF | 0.33% | 0.26% | 0.31% | 0.21% | 0.20% | 0.17% | 0.19% | 0.30% | 0.19% | 0.03% | 0.15% | 0.03% |
Drawdowns
IDNA vs. IBB - Drawdown Comparison
The maximum IDNA drawdown since its inception was -68.26%, which is greater than IBB's maximum drawdown of -62.85%. Use the drawdown chart below to compare losses from any high point for IDNA and IBB. For additional features, visit the drawdowns tool.
Volatility
IDNA vs. IBB - Volatility Comparison
The current volatility for iShares Genomics Immunology and Healthcare ETF Genomics Immunology and Healthcare Fund (IDNA) is 6.80%, while iShares Nasdaq Biotechnology ETF (IBB) has a volatility of 7.16%. This indicates that IDNA experiences smaller price fluctuations and is considered to be less risky than IBB based on this measure. The chart below showcases a comparison of their rolling one-month volatility.